Related Experiment Video
Updated: Jan 31, 2026

Visualization of Pseudomonas aeruginosa within the Sputum of Cystic Fibrosis Patients
Published on: July 16, 2020
[Follow-up protocol of patients with cystic fibrosis diagnosed by newborn screening]
Silvia Gartner1, Pedro Mondéjar-López2, Óscar Asensio de la Cruz3
1Unidad de Fibrosis Quística y Neumología Pediátrica, Hospital Universitari Vall d́Hebron, Barcelona, España.
Insights
Newborn screening for cystic fibrosis (CF) enables early diagnosis and treatment to prevent lung damage. An updated guide is needed due to varied strategies across Spain since 2015.
Area of Science:
- Pediatrics
- Genetics
- Public Health
Background:
- Newborn screening (NBS) for cystic fibrosis (CF) allows early diagnosis and treatment, crucial for preventing irreversible lung damage.
- CF NBS programs have expanded significantly in Spain, with all autonomous regions offering it since 2015.
- Diverse screening and diagnostic strategies currently exist across different Spanish regions.
Purpose of the Study:
- To provide an updated and consensual guide for the diagnosis, follow-up, and treatment of patients identified through neonatal screening for CF.
- To address the heterogeneity in current CF NBS practices across Spain.
Main Methods:
- Review of existing newborn screening protocols for cystic fibrosis in Spain.
- Analysis of diagnostic, follow-up, and treatment strategies implemented in various autonomous regions.
- Consensus-building process for developing updated guidelines.
Main Results:
- Newborn screening for CF is widely implemented across Spain.
- Significant variations in screening protocols and diagnostic pathways are observed.
- There is a recognized need for standardized guidelines.
Conclusions:
- An updated, consensus-driven guide is essential for optimizing CF care in Spain.
- Standardization of diagnosis, follow-up, and treatment following NBS will improve patient outcomes.
- Early intervention through NBS remains critical for managing cystic fibrosis.
Abstract:
Newborn screening (NBS) for cystic fibrosis (CF) is well-established in many countries and provides the opportunity for an early diagnosis and treatment before the development of irreversible structural lung damage. In 1999, Catalonia, Castilla-León, and the Balearic Islands started the NBS programme for CF. In the last 10 years its implementation rapidly spread and all the autonomies offer the NBS programme for CF since 2015. There are many different strategies across Spain. It is believed that it is very opportune to have an updated and consensual guide for the diagnosis, follow-up, and treatment of patients diagnosed by neonatal screening.
More Related Videos
07:04Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
Published on: February 11, 2017
05:56Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
Published on: August 29, 2025
Related Concept Videos
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Cystic Fibrosis: Management
Sinus disease and chronic...
Diagnosing Acidosis and Alkalosis
First, the pH level is assessed to determine whether the blood pH is normal (7.35–7.45), low (acidosis), or high (alkalosis).
Next, the PCO2 and...
Genetic Screens
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
Patient-centered Care
Drug Dosing: Geriatric Patients